The Personalized Medicine Opportunity
This article was originally published in Start Up
Personalized medicine is a field as vast as the differences between individuals, and encompasses technologies, markets, and treatment strategies ranging from autologous cancer vaccines to molecular diagnostics and gene-targeted drugs to methods for visualizing subtle differences in tissues--the foci of the three companies profiled herein.
You may also be interested in...
Xanthus is pursuing personalized medicine in a way quite different from pharmacogenomics players: rather than exclude patients from treatment, this start-up aims to optimize drug dosing for everyone--beginning with anti-cancer compounds. Instead of relying on genes that may or may not be activated, Xanthus is gauging phenotypic factors, traits that are already physically manifest.
The importance of tissue analysis in diagnosing and characterizing disease, notably cancer, can't be underestimated. But analysis of tissue as a source of predictive medical information has been slow to evolve. Aureon Biosciences is changing this situation by developing a new tissue analysis platform to create predictive tests that oncologists can use to guide selection of cancer treatments.
Favrille Inc. believes that it has found a way to significantly curtail cycle time for vaccine production, putting it in position to implement a workable business model for patient-specific therapies for lymphoma and diseases of the immune system.